menu
    • menu
    [{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minzasolmin","moa":"SNCA","graph1":"Neurology","graph2":"Phase II","graph3":"Neuropore Therapies","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.46000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"Neuropore Therapies \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Neuropore Therapies \/ Celerion"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NPT1220-478","moa":"Toll-like-2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuropore Therapies \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore Therapies \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"NPT1220-312","moa":"Toll-like-2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuropore Therapies \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore Therapies \/ ALS Association"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuropore Therapies

    Menu

    Neuropore Therapies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT1220-478

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $4.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research to Suppo...

                            Details : The grant will be used to support the preclinical and clinical development a of a novel brain-penetrating small molecule NPT1220-478, Toll-Like receptor 2 antagonist and maintaining a harmful neuro- inflammatory condition in Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 19, 2022

                            Lead Product(s) : NPT1220-478

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $4.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : $460.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement wit...

                            Details : UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration entered into between Neuropore Therapies and UCB Biopharma on December, 2014. This milestone payment is a result of the continued clinical ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Minzasolmin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : UCB Pharma S.A

                            Deal Size : $460.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT1220-312

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Neuropore Therapies Receives $500,000 Grant

                            Details : The funding will support the preclinical evaluation and development of Neuropore's leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 17, 2020

                            Lead Product(s) : NPT1220-312

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Association

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed...

                            Details : The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 13, 2020

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 17, 2019

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Neuropore Therapies

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT200-11

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of NPT200-11 in Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 17, 2015

                            Lead Product(s) : NPT200-11

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth